Department of Epidemiology and Preventive Medicine, Melbourne, Victoria, AustraliaMonash University, Melbourne Medical School, University of Melbourne, Melbourne, Victoria, Australia
Correspondence: Address to Richard Ofori-Asenso, MSc, PhD, Department of Epidemiology and Preventive Medicine, Monash University, 553 St Kilda Road, Melbourne, Australia, VIC 3004
Affiliations
Department of Epidemiology and Preventive Medicine, Melbourne, Victoria, AustraliaDepartment of Pharmacy, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark
To estimate the prevalence of olfactory and gustatory dysfunctions (OGDs) among patients infected with novel coronavirus disease 2019 (COVID-19).
Methods
A systematic review was conducted by searching MEDLINE, EMBASE, and the preprint server MedRxiv from their inception until May 11, 2020, using the terms anosmia or hyposmia or dysosmia or olfactory dysfunction or olfaction disorder or smell dysfunction or ageusia or hypogeusia or dysgeusia or taste dysfunction or gustatory dysfunction or neurological and COVID-19 or 2019 novel coronavirus or 2019-nCoV or SARS-CoV-2. The references of included studies were also manually screened. Only studies involving patients with diagnostic-confirmed COVID-19 infection were included. Random-effects meta-analysis was performed.
Results
Twenty-four studies with data from 8438 patients with test-confirmed COVID-19 infection from 13 countries were included. The pooled proportions of patients presenting with olfactory dysfunction and gustatory dysfunction were 41.0% (95% CI, 28.5% to 53.9%) and 38.2% (95% CI, 24.0% to 53.6%), respectively. Increasing mean age correlated with lower prevalence of olfactory (coefficient = −0.076; P=.02) and gustatory (coefficient = −0.073; P=.03) dysfunctions. There was a higher prevalence of olfactory dysfunctions with the use of objective measurements compared with self-reports (coefficient = 2.33; P=.01). No significant moderation of the prevalence of OGDs by sex was observed.
Conclusion
There is a high prevalence of OGDs among patients infected with COVID-19. Routine screening for these conditions could contribute to improved case detection in the ongoing COVID-19 pandemic. However, to better inform population screening measures, further studies are needed to establish causality.
Novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an outbreak that emerged in China in December 2019, has rapidly evolved into a global pandemic.
To contain the outbreak, effective screening, rapid diagnosis, and isolation of infected individuals are essential. These measures require sound understanding of the clinical presentation of the disease. Early observations in China revealed several nonspecific signs and symptoms related to COVID-19 infection, including fever, dry cough, dyspnea, myalgia, and anorexia.
The use of Google trends to investigate the loss of smell related searches during COVID-19 outbreak [published online ahead of print April 11, 2020]. Int Forum Allergy Rhinol.
have noted an increase in Internet searches for smell-related information in several countries and hypothesize that smell dysfunction may be an under-recognized symptom of COVID-19 infection. Consequently, the British Association of Otorhinolaryngology
proposed that symptoms of OGDs be added to the list of screening tools for possible COVID-19 infection. Nevertheless, the proportion and characteristics of patients infected with COVID-19 who experience OGDs are not thoroughly understood.
Thus, we conducted a systematic review and meta-analysis to estimate the prevalence of OGDs among patients infected with COVID-19. We also examined the potential effects of factors such as age, sex, and assessment method on the prevalence of OGDs. At the time of commencing this review (May 3, 2020), no systematic review and meta-analysis on the topic had been published.
Methods
This systematic review follows the recommendations outlined in the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement
(Supplemental Table 1, available online at http://www.mayoclinicproceedings.org). Given the urgent need for information to inform clinical decision making in the context of the COVID-19 pandemic, prior registration of the review protocol was not feasible.
Database Search
To identify appropriate studies for the review, searches were performed in MEDLINE, EMBASE, and the preprint server MedRxiv using the terms anosmia or hyposmia or dysosmia or olfactory dysfunction or olfaction disorder or smell dysfunction or ageusia or hypogeusia or dysgeusia or taste dysfunction or gustatory dysfunction or neurological and COVID-19 or 2019 novel coronavirus or 2019-nCoV or SARS-CoV-2 (Supplemental Table 2, available online at http://www.mayoclinicproceedings.org). The search was initially performed on May 3, 2020, and last updated on May 11, 2020. No language restrictions were applied. The reference lists of included studies were also hand-searched for additional articles.
Study Selection and Evaluation
Only studies with data for patients with test-confirmed COVID-19 status were eligible for inclusion. Moreover, because our objective was to estimate the prevalence of smell and taste dysfunctions separately, studies that reported a composite of smell and taste dysfunction without presenting individual data for each outcome were excluded. When studies from the same center recruiting patients during the same period were present, we selected the one with the larger sample size or more detailed information. Furthermore, we excluded case series involving fewer than 10 patients, as well as commentaries, editorials, and reviews.
Quality Assessment
The methodological quality of each study was assessed using a tool developed by Murad et al.
This tool involves 8 items under 4 domains: selection, ascertainment, causality, and reporting (Supplemental Table 3, available online at http://www.mayoclinicproceedings.org). Only items applicable to the studies included in the review were evaluated. Numeric scoring was not performed and an overall judgment about methodological quality of the included studies was made as per the questions deemed most critical in the specific clinical scenario.
Data were extracted independently by 2 reviewers (A.A.A. and R.O.-A.), and any disagreements were resolved through consensus. For each study, first author name, country, participant mean age, proportion of females, and percentage with smell or taste disorders were extracted. If a study assessed OGDs based on patients’ self-report and objective measurements, we prioritized the data from the objective assessments.
Analyses were conducted using Stata SE software, version 16 (StataCorp). Meta-analysis of prevalence was conducted using the STATA Metaprop command,
Owing to the anticipated between-study heterogeneity, a random-effects model was used. Between-study heterogeneity was quantified using the I2 statistic.
An I2>50% was considered to represent substantial heterogeneity. Leave-1-out sensitivity analyses were performed to assess the stability of pooled estimates. Using the STATA Metareg command,
meta-regression was conducted to determine the influence of study mean age, proportion of females, assessment method (subjective vs objective), and region of study (Europe vs other) on the pooled prevalence. The syntax for the metaregression was “Metareg logitEventRate age [proportion of females] region [assessment method], wsse(logitEventSE),” where logitEventRate=log(p/(1 − p)) and logitEventSE=[sqrt(1/(p×Total) + 1/((1 − p)×Total))], and p indicates proportion and Total indicates sample size. A 2-tailed P<.05 was considered significant. Because our study relied on published literature, institutional ethical review was not required.
Results
Study Characteristics
The searches in MEDLINE and EMBASE retrieved 341 citations. Following removal of duplicates and screening of titles and abstracts, 52 articles were selected for full-text evaluation. Fifteen articles were retained after full-text assessment. Nine additional studies were identified from the preprint server, resulting in 24 studies being included in the review (Figure 1).
Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020.
Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study [published online ahead of print March 26, 2020]. Clin Infect Dis.
Clinical features of 95 sequential hospitalised patients with novel coronavirus 2019 disease (COVID-19), the first UK cohort [published online ahead of print April 27, 2020]. J Infect.
Self-reported olfactory loss associates with outpatient clinical course in COVID-19 [published online ahead of print April 24, 2020]. Int Forum Allergy Rhinol.
Beltrán-Corbellini Á Acute-onset smell and taste disorders in the context of Covid-19: a pilot multicenter PCR-based case-control study [published online ahead of print April 22, 2020]. Eur J Neurol.
Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China [published online ahead of print April 10, 2020]. JAMA Neurol.
Clinical and epidemiological characteristics of 1,420 European patients with mild-to-moderate coronavirus disease 2019 [published online ahead of print April 30, 2020]. J Intern Med.
Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States.
Distinguishing between COVID-19 and the common cold in a primary care setting - comparison of patients with positive and negative SARS-CoV-2 PCR results [preprint posted May 5, 2020]. MedRxiv.
Clinical presentation and evolution of COVID-19 in immunosuppressed patients. Preliminary evaluation in a North Italian cohort on calcineurin-inhibitors based therapy [preprint posted May 1, 2020]. MedRxiv. 2020.
Multivariable prediction model of intensive care unit transfer and death: a French prospective cohort study of COVID-19 patients [preprint posted May 8, 2020]. MedRxiv.
Validation of a self-administered olfactory and gustatory test for the remotely evaluation of COVID-19 patients in home quarantine [published online ahead of print May 1, 2020]. Head Neck.
Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China [published online ahead of print April 10, 2020]. JAMA Neurol.
Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020.
Clinical features of 95 sequential hospitalised patients with novel coronavirus 2019 disease (COVID-19), the first UK cohort [published online ahead of print April 27, 2020]. J Infect.
Self-reported olfactory loss associates with outpatient clinical course in COVID-19 [published online ahead of print April 24, 2020]. Int Forum Allergy Rhinol.
Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States.
Multivariable prediction model of intensive care unit transfer and death: a French prospective cohort study of COVID-19 patients [preprint posted May 8, 2020]. MedRxiv.
Distinguishing between COVID-19 and the common cold in a primary care setting - comparison of patients with positive and negative SARS-CoV-2 PCR results [preprint posted May 5, 2020]. MedRxiv.
Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study [published online ahead of print March 26, 2020]. Clin Infect Dis.
Clinical presentation and evolution of COVID-19 in immunosuppressed patients. Preliminary evaluation in a North Italian cohort on calcineurin-inhibitors based therapy [preprint posted May 1, 2020]. MedRxiv. 2020.
Validation of a self-administered olfactory and gustatory test for the remotely evaluation of COVID-19 patients in home quarantine [published online ahead of print May 1, 2020]. Head Neck.
Beltrán-Corbellini Á Acute-onset smell and taste disorders in the context of Covid-19: a pilot multicenter PCR-based case-control study [published online ahead of print April 22, 2020]. Eur J Neurol.
Clinical and epidemiological characteristics of 1,420 European patients with mild-to-moderate coronavirus disease 2019 [published online ahead of print April 30, 2020]. J Intern Med.
The studies involved a total of 8438 patients. The reported mean age ranged from 34.0 to 77.0 years, and 58.7% (4785 of 8150; 20 studies) of the patients were females (Table).
Figure 1Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart of study selection process.
Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020.
Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study [published online ahead of print March 26, 2020]. Clin Infect Dis.
Clinical features of 95 sequential hospitalised patients with novel coronavirus 2019 disease (COVID-19), the first UK cohort [published online ahead of print April 27, 2020]. J Infect.
Self-reported olfactory loss associates with outpatient clinical course in COVID-19 [published online ahead of print April 24, 2020]. Int Forum Allergy Rhinol.
Beltrán-Corbellini Á Acute-onset smell and taste disorders in the context of Covid-19: a pilot multicenter PCR-based case-control study [published online ahead of print April 22, 2020]. Eur J Neurol.
Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China [published online ahead of print April 10, 2020]. JAMA Neurol.
Clinical and epidemiological characteristics of 1,420 European patients with mild-to-moderate coronavirus disease 2019 [published online ahead of print April 30, 2020]. J Intern Med.
Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States.
Distinguishing between COVID-19 and the common cold in a primary care setting - comparison of patients with positive and negative SARS-CoV-2 PCR results [preprint posted May 5, 2020]. MedRxiv.
Clinical presentation and evolution of COVID-19 in immunosuppressed patients. Preliminary evaluation in a North Italian cohort on calcineurin-inhibitors based therapy [preprint posted May 1, 2020]. MedRxiv. 2020.
Multivariable prediction model of intensive care unit transfer and death: a French prospective cohort study of COVID-19 patients [preprint posted May 8, 2020]. MedRxiv.
Validation of a self-administered olfactory and gustatory test for the remotely evaluation of COVID-19 patients in home quarantine [published online ahead of print May 1, 2020]. Head Neck.
CCCRC = Connecticut Chemosensory Clinical Research Center; NHANES = National Health and Nutrition Examination Survey; NR = not reported; OGD = olfactory and gustatory dysfunction; UPSIT = University of Pennsylvania Smell Identification Test.
The methodological assessment of the individual studies is presented in Supplemental Table 4 (available online at http://www.mayoclinicproceedings.org). Because our review included only patients with COVID-19 infection with diagnostic confirmation, bias from nonascertainment of exposure was minimized. However, very few studies had reported use of objective assessment of OGDs, with most relying on unvalidated questionnaires. Thus, studies may experience ascertainment bias. Most studies (20/24; 83%) did not explore other potential causes that may explain the outcome, and they could not establish with certainty that OGDs were absent before COVID-19 infection and therefore causality cannot be implied.
Olfactory Dysfunctions
Of the 24 studies that reported the prevalence of olfactory dysfunction, 21% (5/24) used objective assessments, whereas the rest (19/24; 79%) mainly relied on self-reports. The reported prevalence of olfactory dysfunction ranged from 3.2% to 98.3%, and the pooled prevalence was 41.0% (95% CI, 28.5% to 53.9%; I2=99.1%; Figure 2). A leave-1-out sensitivity analysis did not significantly change the results (point estimate ranged from 38.1% to 42.1%). The pooled prevalence tended to decrease with increasing mean age of study participants (coefficient = −0.076; 95% CI, −0.135 to −0.016; P=.02) and was higher when objective measurements were used compared with self-reports (coefficient = 2.33; 95% CI, 0.57 to 4.09; P=.01) but was not significantly moderated by sex (coefficient = −0.018; 95% CI, −0.062 to 0.026; P=.39) or study region (coefficient = 0.564; 95% CI, −0.818 to 1.946; P=.40). The variables included in the metaregression altogether explained 51.7% of the between-study variance relative to the prevalence of olfactory dysfunctions. There was no strong evidence of publication bias (funnel plot, Supplemental Figure 1, available online at http://www.mayoclinicproceedings.org; Eggers test, P=.306).
Figure 2Forest plot of proportion of patients with novel coronavirus disease 2019 infection presenting with olfactory dysfunction. ES = proportion; n = number of patients with olfactory dysfunction; N = sample size.
Fifteen studies involving 5649 patients reported the prevalence of gustatory dysfunctions. Among these, 13% (2/15) used objective assessments, whereas the rest (13/15; 87%) relied mainly on self-reports. The reported prevalence of gustatory dysfunctions ranged from 5.6% to 62.7%, and the pooled prevalence was 38.2% (95% CI, 24.0% to 53.6%; I2=98.8; Figure 3). A leave-1-out sensitivity analysis did not significantly change the results (point estimate ranged from 36.1% to 41.2%). The pooled prevalence tended to decrease with increasing mean age (coefficient = −0.073; 95% CI, −0.136 to −0.009; P=.03) and was slightly higher across European studies than studies from elsewhere (coefficient = 1.195; 95% CI, 0.118 to 2.272; P=.03). There was no significant moderation by sex (coefficient = −0.022; 95% CI, −0.066 to 0.022; P=.29) or assessment methods (coefficient = 0.439; 95% CI, −1.192 to 2.071; P=.56). The variables included in the metaregression altogether explained 47.9% of the between-study variance relative to the prevalence of gustatory dysfunctions. There was no strong evidence of publication bias (funnel plot, Supplemental Figure 2, available online at http://www.mayoclinicproceedings.org; Eggers test, P=.604).
Figure 3Forest plot of proportion of patients with novel coronavirus disease 2019 infection presenting with gustatory dysfunction. ES = proportion; n = number of patients with gustatory dysfunction; N = sample size.
In this systematic review and meta-analysis, we found that about 41% and 38% of diagnostic-confirmed patients with COVID-19 infection presented with olfactory or gustatory dysfunctions, respectively. Increasing age correlated with lower prevalence of OGDs, whereas the use of objective assessment methods correlated with higher prevalence of olfactory dysfunction. No significant moderation of the prevalence of OGDs by sex was noted.
The exact mechanisms underlying OGDs among patients with COVID-19 infection remain unclear. However, olfactory impairment after upper respiratory tract infection is a common occurrence in clinical settings. In particular, postviral olfactory dysfunction has been implicated in 40% of cases of anosmia in adults,
Olfactory dysfunction in COVID-19 infection could be related to the involvement of the olfactory bulb or to peripheral damage of the olfactory receptor cells in the nasal neuroepithelium.
This assertion is based on the potential neurotrophic features of SARS-CoV-2. In particular, it has been demonstrated in transgenic mice that after intranasal administration of SARS-CoV (which shares similarities with SARS-CoV-2), the virus could penetrate into the brain through the olfactory bulb, leading to rapid transneuronal spread.
Previously, epithelial cells lining salivary gland ducts were found to be early target cells of SARS coronavirus infection in the upper respiratory tracts of rhesus macaques.
Epithelial cells lining salivary gland ducts are early target cells of severe acute respiratory syndrome coronavirus infection in the upper respiratory tracts of rhesus Macaques.
Phylogenetic similarities between SARS-CoV and SARS-CoV-2 mean that the latter could also alter gustatory sensation in affected patients.
The few studies that have evaluated the clinical utility of OGDs in COVID-19 diagnosis have suggested their low sensitivity (23%-43%) and high specificity (93%-99%).
The role of self-reported olfactory and gustatory dysfunction as a screening criterion for suspected COVID-19 [published online ahead of print April 24, 2020]. Eur Arch Otorhinolaryngol.
Regardless, in one study, the sensitivity and specificity of OGDs were reported to be comparable to the sensitivity and specificity of a history of close contact with a confirmed COVID-19 case.
The role of self-reported olfactory and gustatory dysfunction as a screening criterion for suspected COVID-19 [published online ahead of print April 24, 2020]. Eur Arch Otorhinolaryngol.
An analysis of 237 entries from the AAO-HNS COVID-19 Anosmia Reporting Tool suggested that anosmia was noted in 73% of patients before the COVID-19 diagnosis and was the initial symptom in 26.6%.
Self-reported olfactory loss associates with outpatient clinical course in COVID-19 [published online ahead of print April 24, 2020]. Int Forum Allergy Rhinol.
have also suggested that OGDs may be associated with a milder course of COVID-19 infection. This may also potentially explain the lower prevalence of OGDs with increasing mean age because older people are more likely to experience severe COVID-19 infection compared with younger individuals.
Consequently, the potential higher burden of OGDs in patients with milder COVID-19 disease is concerning because such patients may be less likely to be tested but could continue to spread the virus. Thus, public education about symptoms of OGDs may be necessary, and patients experiencing such symptoms should be advised to self-isolate pending confirmatory testing.
It is not yet clear whether the COVID-19–related OGDs are transient or permanent. However, among 23 patients with COVID-19 infection with anosmia in Iran, 75% reported significant improvement over 2 weeks.
Distinguishing between COVID-19 and the common cold in a primary care setting - comparison of patients with positive and negative SARS-CoV-2 PCR results [preprint posted May 5, 2020]. MedRxiv.
Moreover, among 237 patients with anosmia on the AAO-HNS COVID-19 Anosmia Reporting platform, 27% reported improvement in symptoms, with the mean time to improvement being 7.2 days.
Owing to the high occurrence of anosmia in COVID-19–positive individuals, the indiscriminate use of corticosteroids, particularly in the absence of known head trauma or allergic symptoms, should be discouraged because corticosteroids may escalate COVID-19 infection.
Anosmia, hyposmia, and dysgeusia as indicators for positive SARS-CoV-2 infection [published online ahead of print April 17, 2020]. World J Otorhinolaryngol Head Neck Surg.
The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: a systematic review and meta-analysis [published online ahead of print May 5, 2020]. Otolaryngol Head Neck Surg.
reported the pooled prevalence of olfactory and gustatory dysfunction among patients with COVID-19 infection as 52.73% (95% CI, 29.64% to 75.23%) and 43.93% (95% CI, 20.46% to 68.95%), respectively, their analysis was based on 10 studies and involved fewer than 1700 patients. Our study has provided pooled prevalence estimates of OGDs based on data from 24 studies involving more than 8400 patients with diagnostic-confirmed COVID-19 infection from 13 countries. Furthermore, our analysis provides new insights into the potential role of individual-level characteristics such as age and sex in the presentation of OGDs among patients with COVID-19 infection that were not explored in the study by Tong et al.
The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: a systematic review and meta-analysis [published online ahead of print May 5, 2020]. Otolaryngol Head Neck Surg.
Despite the strengths of our study, the findings should be interpreted in light of some limitations. There was high statistical heterogeneity, which is largely attributable to the observational nature of the studies. Further investigations revealed that the heterogeneity was not entirely explained by differences in patients' age, proportion of females, region, or OGD assessment methods.
From a methodological perspective, the design of most of the included studies preclude the confirmation of causality between COVID-19 and OGDs. Thus, to better inform population screening measures, further well-designed prospective studies using validated or objective measurement techniques are needed to establish causality. Most studies also recruited patients in European settings, which may affect the generalizability of our findings.
Moreover, few studies used objective assessment methods for establishing the presence of OGDs, whereas most relied on self-reports. These may lead to bias in the ascertainment of OGDs. For example, it is possible for patients to confuse taste function and aroma sense perception,
that made this distinction, among 28 patients with COVID-19 infection, 86% experienced aroma disorders, whereas 60.7% experienced taste disorders. However, it was unclear what proportion of patients experienced both symptoms.
Last, because the metaregression relied on study-level characteristics such as mean age and proportion of females, ecological fallacy cannot be entirely ruled out.
This study found a high prevalence of OGDs among patients infected with COVID-19. Hence, the consideration of OGDs as part of the screening and diagnostic approaches for COVID-19 could help improve case detection and further curtail the spread of the virus. However, to better inform population screening measures, further well-designed studies are needed to establish causality between COVID-19 and the occurrence of OGDs.
Supplemental material can be found online at http://www.mayoclinicproceedings.org. Supplemental material attached to journal articles has not been edited, and the authors take responsibility for the accuracy of all data.
The use of Google trends to investigate the loss of smell related searches during COVID-19 outbreak [published online ahead of print April 11, 2020]. Int Forum Allergy Rhinol.
Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020.
Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study [published online ahead of print March 26, 2020]. Clin Infect Dis.
Clinical features of 95 sequential hospitalised patients with novel coronavirus 2019 disease (COVID-19), the first UK cohort [published online ahead of print April 27, 2020]. J Infect.
Self-reported olfactory loss associates with outpatient clinical course in COVID-19 [published online ahead of print April 24, 2020]. Int Forum Allergy Rhinol.
Acute-onset smell and taste disorders in the context of Covid-19: a pilot multicenter PCR-based case-control study [published online ahead of print April 22, 2020]. Eur J Neurol.
Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China [published online ahead of print April 10, 2020]. JAMA Neurol.
Clinical and epidemiological characteristics of 1,420 European patients with mild-to-moderate coronavirus disease 2019 [published online ahead of print April 30, 2020]. J Intern Med.
Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States.
Distinguishing between COVID-19 and the common cold in a primary care setting - comparison of patients with positive and negative SARS-CoV-2 PCR results [preprint posted May 5, 2020]. MedRxiv.
Clinical presentation and evolution of COVID-19 in immunosuppressed patients. Preliminary evaluation in a North Italian cohort on calcineurin-inhibitors based therapy [preprint posted May 1, 2020]. MedRxiv. 2020.
Multivariable prediction model of intensive care unit transfer and death: a French prospective cohort study of COVID-19 patients [preprint posted May 8, 2020]. MedRxiv.
Validation of a self-administered olfactory and gustatory test for the remotely evaluation of COVID-19 patients in home quarantine [published online ahead of print May 1, 2020]. Head Neck.
Epithelial cells lining salivary gland ducts are early target cells of severe acute respiratory syndrome coronavirus infection in the upper respiratory tracts of rhesus Macaques.
The role of self-reported olfactory and gustatory dysfunction as a screening criterion for suspected COVID-19 [published online ahead of print April 24, 2020]. Eur Arch Otorhinolaryngol.
Anosmia, hyposmia, and dysgeusia as indicators for positive SARS-CoV-2 infection [published online ahead of print April 17, 2020]. World J Otorhinolaryngol Head Neck Surg.
The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: a systematic review and meta-analysis [published online ahead of print May 5, 2020]. Otolaryngol Head Neck Surg.
If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
30546-2&id=gr1.jpg){kind=link}
30546-2&id=gr2.jpg){kind=link}
30546-2&id=gr3.jpg){kind=link}